

OSCIENT PHARMACEUTICALS CORP
Form 8-K
September 11, 2006

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to

Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): September 11, 2006

OSCIENT PHARMACEUTICALS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction

0-10824
(Commission File Number)

04-2297484
(I.R.S. Employer

of incorporation)

Identification Number)

1000 Winter Street, Suite 2200

Waltham, Massachusetts 02451

(Address of principal executive offices, including zip code)

(781) 398-2300

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

.. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 8-K

- “ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 - “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 - “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 8.01. OTHER EVENTS.

Oscient Pharmaceuticals Corporation (the Company) today reported that, in advance of the Anti-Infective Drugs Advisory Committee meeting scheduled for Tuesday, September 12, 2006 to discuss the Company's pending supplemental New Drug Application seeking approval of FACTIVE® (gemifloxacin mesylate) tablets for the treatment of acute bacterial sinusitis, the U.S. Food and Administration (FDA) has posted the briefing documents associated with the meeting. The briefing documents are available on the FDA's website at <http://www.fda.gov/ohrms/dockets/ac/cder06.html#AntiInfective>.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OSCIENT PHARMACEUTICALS CORPORATION

By: /s/ Steven M. Rauscher
Name: Steven M. Rauscher
Title: President and Chief Executive Officer

Date: September 11, 2006